I find this news item very interesting. The Medicare program has been strengthening the oversight of drug therapy in nursing homes and now a “consulting pharmacist” is required to review a nursing home patient’s medication record monthly. If atypical antipsychotics are being overprescribed, it raises a few questions in my mind. Is the failure with consulting pharmacists who are not recommending the termination of these drugs when used inappropriately? Or does the failure lie with the physician or staff member who overrides the recommendation to discontinue the therapy?
This news item suggests that Grassley and Kohl think PBMs may play a role. I thought PBMs were interested in not paying for unnecessary drugs, so how do they increase the usage of antipsychotics if they are not indicated? Could the problem be related more to the desire to treat dementia with anything even if it is not likely to work? Can you help me understand what may be going on here?
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs